Skip to main content
M

Many Bright Ideas Technologies Inc. — Investor Relations & Filings

Ticker · MBI.H TSXV Professional, scientific and technical activities
Open in API
Filings indexed 83 across all filing types
Latest filing 2026-04-24 Regulatory Filings
Country CA Canada
Listing TSXV MBI.H

About Many Bright Ideas Technologies Inc.

https://www.medbiogene.com/

Many Bright Ideas Technologies Inc. is a technology commercialization company focused on the acquisition, development, and commercialization of intellectual property across various industrial sectors, emphasizing alternative non-medical technologies. The company maintains a significant legacy interest in the life sciences domain. Its primary licensed asset is GeneFx® Lung, a proprietary gene expression-based diagnostic test. GeneFx® Lung is designed to assist in personalized treatment decisions for patients with early-stage non-small-cell lung cancer (NSCLC) by predicting mortality risk and identifying those who may benefit from adjuvant chemotherapy. Exclusive global rights for the development and commercialization of GeneFx® Lung are held by Precision Therapeutics, Inc.

Recent filings

Filing Released Lang Actions
Notice of the meeting and record date - English.pdf
Regulatory Filings Classification · 1% confidence The document is a notice from the transfer agent to Canadian securities regulators detailing the record date, meeting date, and logistical information for the issuer’s upcoming Annual General Meeting. It does not contain AGM presentations or proxy materials (AGM-R/PSI), nor is it a financial report, dividend, or other specific filing. It serves as a regulatory notification about the meeting, best fitting the fallback category for miscellaneous regulatory announcements (RNS).
2026-04-24 English
Notice of the meeting and record date - English.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice of the upcoming Annual General Meeting (AGM) of Many Bright Ideas Technologies Inc., providing record dates, meeting date, location, and proxy delivery details. These are proxy solicitation materials (Notice of Meeting) prepared for regulators and shareholders in connection with the AGM. Under our taxonomy, such notice and related proxy materials fall under “Proxy Solicitation & Information Statement” (PSI).
2026-04-24 English
Statement of executive compensation (form 51-102F6) - English.pdf
M&A Activity Classification · 1% confidence The document is a corporate press release providing an update on a proposed acquisition of Arion Defense and a related trading halt. It details transaction terms, strategic rationale, required approvals, and financing aspects specifically tied to a merger/acquisition. This aligns with an M&A Activity announcement (Code: TAR). It is not a financial report, dividend notice, or regulatory filing announcement but an M&A transaction update.
2026-04-17 English
Statement of executive compensation (form 51-102F6) - English.pdf
Remuneration Information Classification · 1% confidence The document is titled “Form 51-102F6 Statement of Executive Compensation” for the year ended December 31, 2025 under Canadian NI 51-102. It provides detailed analysis of Named Executive Officer compensation, summary compensation tables, incentive plan awards, pension benefits, terminal and change of control benefits, and director compensation. This is a standalone executive compensation disclosure and corresponds to our “Remuneration Information” category.
2026-04-17 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a 'Form 52-109FV2', which is a Venture Issuer Basic Certificate used for the certification of interim filings in Canada. It is a regulatory requirement that accompanies interim financial reports to confirm the accuracy of the filings. Since it is a regulatory certification document rather than the financial report itself, and it does not fit into the specific categories like '10-K' or 'IR', it is best classified as a Regulatory Filing (RNS).
2025-11-25 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a 'Form 52-109FV2', which is a Venture Issuer Basic Certificate for interim filings. This is a regulatory certification document required by Canadian securities legislation to accompany interim financial reports. Since it is a regulatory filing that does not fit into the specific categories of financial reports, management reports, or announcements, it falls under the 'Regulatory Filings' category.
2025-11-25 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.